Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

MEDIA RELEASE

  • Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years[1]
  • Intended acquisition would reinforce in-house biosimilar development and manufacturing capabilities, while creating additional strategic flexibility
  • Sandoz would acquire Just-Evotec Biologics (JEB) activities in Toulouse, France, including proprietary platform for integrated development and advanced continuous manufacturing

Basel, July 30, 2025   Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announced today that it has signed a non-binding term sheet with Evotec SE. This paves the way for Sandoz to potentially acquire 100% of the issued and outstanding equity interests of Just–Evotec Biologics EU SAS for an amount of around USD 300 million, which owns the J.POD biologics development and manufacturing facility in Toulouse, France.

Richard Saynor, CEO of Sandoz, said: “We aim to capitalize on the projected USD 300 billion biosimilar market opportunity over the next decade. The intended acquisition is fully in line with our strategy to reinforce in-house biosimilar capabilities, while creating additional strategic flexibility. Following successful completion, the Toulouse site would be used to develop and manufacture Sandoz biosimilars. JEB´s fully automated and high throughput technology platform will help us move faster, scale smarter, and maintain high quality while keeping costs under control.”

Sandoz and Evotec SE will now work to negotiate details of the contracts and carry out the relevant works-council consultation processes, as well as the mandatory employee bid process in France. Closing the proposed transaction will be subject to finalizing the contracts and obtaining all necessary approvals. Further details of the terms cannot be shared at this stage and will only be disclosed after successful signing of the contracts.

Just-Evotec Biologics has been a key strategic partner for Sandoz since 2023. The proposed acquisition would complement previously announced investments in Sandoz biosimilar manufacturing and development sites. The planned investment would be in line with existing Sandoz capital-expenditure commitments related to Sandoz operations in Europe.

Upon completion of the proposed transaction, JEB employees would transfer with the acquired entity and would become part of the Sandoz Group. JEB brings an advanced and integrated continuous manufacturing platform with automation that enables manufacturing to run continuously end-to-end.

Based on March 2025 data from IPD Analytics Evaluate Pharma, covering the period 2026–2035.

About Sandoz agreement with JEB

In May 2023, Sandoz and JEB announced a strategic partnership that supports the company’s portfolio expansion and continued development of its early-stage biosimilar pipeline by providing access to JEB’s highly-efficient drug substance development platform. The proprietary fully automated and high throughput technology platform allows Sandoz to continue to build out its own integrated drug substance development and manufacturing network.

JEB is also developing an integrated continuous manufacturing platform with automation that enables the manufacturing process to run continuously end-to-end, resulting in enhanced efficiency and cost-effectiveness.

In July 2024, Sandoz secured long-term commercial supply access to JEB’s biosimilars manufacturing facility in Toulouse, France. In addition, Sandoz secured resource capacity for drug substance development of additional molecules starting in 2025. JEB will also enable the implementation of its design capability and continuous manufacturing technology at Sandoz.

DISCLAIMER
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.

ABOUT SANDOZ
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.

CONTACTS
Global Media Relations contactsInvestor Relations contacts  
Global.MediaRelations@sandoz.comInvestor.Relations@sandoz.com
Alexis Kalomparis
+41 792 790285
Craig Marks
+44 7818 942 383
Joerg E. Allgaeuer
+49 171 838 4838
Rupreet Sandhu
+41 79 410 5472


Attachment

  • Media release_Sandoz TS Just-Evotec_25-07-30

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France


THỦ THUẬT HAY

4 cách xử lý iPhone bị đơ khi đang sử dụng

Tình trạng đang sử dụng mà iPhone bị đứng không phải là quá xa lạ. Nếu tình trạng này xảy ra với tần suất thấp thì không có gì phải nói, còn ngược...

Smartphone Android chạy chậm, xử lý làm sao?

Chậm, lag là hiện tượng phổ biến của người dùng smartphone sau một thời gian dài sử dụng, đặc biệt là đối với những điện thoại trong phân khúc giá rẻ và tầm trung. Vậy có cách nào để khắc phục hay không? Cùng tìm hiểu

Hướng dẫn cách gõ tiếng Việt có dấu trên máy tính

Điều kiện cần để bạn có thể gõ được tiếng Việt trên máy tính là phải có cài bộ hỗ trợ gõ tiếng Việt. Có rất nhiều ứng dụng hỗ trợ gõ tiếng Việt nổi bật khác nhau, nhưng chúng tôi chỉ giới thiệu tới các bạn 2 bộ gõ

7 ứng dụng dành cho Android đang miễn phí và giảm giá

Tiếp tục cập nhật danh sách 'Free App' hằng ngày dành cho smartphone Android, TCN đã tổng hợp thêm khá nhiều ứng dụng và game trả phí đang được miễn phí. Nếu bạn quan tâm hãy nhanh tay tải về trước khi bị tính phí trở

Cách cài Windows 10 bằng Hyper-V và cài máy ảo trên Hyper-V

Nếu như bạn đang cần một công cụ, phần mềm để cài Windows 10 hay bất cứ hệ điều hành nào dưới dạng máy ảo thông thường chúng ta sẽ nghĩ đến ngày phần mềm VMWare. Đơn giản vì cài Windows 10 bằng VMWare rất dễ dàng, được

ĐÁNH GIÁ NHANH

So sánh Galaxy Z Fold3 5G và Surface Duo 2: Microsoft có thắng nổi Samsung?

Galaxy Z Fold3 5G và Surface Duo 2 đều là hai chiếc smartphone sở hữu thiết kế vô cùng độc đáo hiện nay. Mời bạn cùng chúng tôi so sánh Galaxy Z Fold3 5G và Surface Duo 2 để xem hai model này có gì khác biệt nhé. So

Đánh giá chi tiết cấu hình và hiệu năng Galaxy A3 2017

Hiện em út dòng A 2017 là thiết bị có số lượng bài viết khá ít ỏi, quyết không để A3 2017 bị ghẻ lạnh. Mời các bạn cùng đến với bài đánh giá chi tiết Galaxy A3 2017 sau một thời gian khá lâu giữ em nó nhé.

So sánh MacBook Pro 2023 và 2021: Liệu có đáng nâng cấp

MacBook Pro 2023 là phiên bản tiếp theo của MacBook Pro 2021 14 inch và 16 inch, cùng so sánh 2 phiên bản này có sự khác nhau như thế nào? Có đáng để nâng cấp trong năm 2023 hay không trong bài viết này.